Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3

Area of Science:

• Biomedical Engineering
• Cell Biology
• Skeletal Biology

Background:

• Osteoporosis is a common skeletal disorder causing bone density loss, affecting millions worldwide.
• Current treatments for osteoporosis primarily focus on slowing bone loss, highlighting a need for therapies that stimulate bone formation.
• A novel peptide, CK2.3, has shown potential in inducing osteogenesis (bone formation) both in vitro and in vivo.

Purpose of the Study:

• To investigate the cellular uptake mechanism of the osteogenic peptide CK2.3.
• To determine how the peptide enters cells, which is crucial for understanding its therapeutic action.

Main Methods:

• Conjugating the peptide CK2.3 to Quantum Dots (Qdots) to create a traceable probe (CK2.3-Qdot).
• Purifying and verifying the CK2.3-Qdot conjugate using chromatography and spectroscopy.
• Utilizing confocal microscopy and pharmacological inhibitors to track internalization and identify the endocytic pathway.

Main Results:

• The CK2.3-Qdot conjugate was successfully created, purified, and demonstrated stability.
• The CK2.3-Qdot conjugate retained the biological activity of the original peptide.
• Confocal imaging showed CK2.3-Qdot internalization into cells by 6 hours post-stimulation.
• Pharmacological inhibition confirmed that cellular uptake occurs via caveolae-mediated endocytosis.

Conclusions:

• The peptide CK2.3 is internalized into cells through caveolae-mediated endocytosis.
• This finding elucidates a key aspect of CK2.3's mechanism of action, paving the way for its therapeutic development in osteoporosis.